Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

eveloper of highly selective ion channel drugs for the treatment of atrial fibrillation.  Utilising its world-leading expertise in the discovery of potent and selective drugs, Xention is focusing on the potassium channels Kv1.5 and IKACh which are widely recognised by cardiologists as the preferred targets for the prevention of atrial fibrillation.  Xention's lead drug candidate XEN-D0103, a Kv1.5 antagonist, is at the end of phase 1 clinical development and has demonstrated a very high degree of selectivity over non-atrial ion channels.  The company has also developed antagonists of IKACh which are highly potent and selective, and an IKACh development candidate will be selected shortly.

Xention has signed two major research collaborations with Ono Pharmaceutical Co Ltd and the Grϋnenthal Group, which take advantage of its strong experience in ion channel discovery and which are focused on the development of clinical candidates in other therapeutic areas.

Xention is based in Cambridge, UK and employs over 50 people. For further information, please visit http://www.xention.com.

For further information, please contact:

Tim Brears, CEO, Xention Limited, +44(0)1223-493-900

Amber Bielecka / Claire Dickinson, M:Communications, xention@mcomgroup.com, +44(0)20-7920-2352


'/>"/>
SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... for odour control projects in North America , ... . "Bidding activity in 2015 continues to be ... a high volume year for bidding in 2014, we are pleased ... recent orders reflect the organization,s renewed focus on select market segments ...
(Date:3/3/2015)... /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences company ... for advanced microarray diagnostics, today announced it has ... Management team. In his capacity as CFO he ... a development stage to a commercially successful company ... capital market strategy and to secure funding to ...
(Date:3/3/2015)... Santa Clara, California (PRWEB) March 03, 2015 ... and development service company, has launched a new Life ... research reagents for preclinical research. , The first ... monoclonal antibody isotype controls, and soon to be released ... The company will continue to expand their life science ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Crown Bioscience Launches Life Science Product Catalog 2
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, today,announced that Ron ... Finance, will attend the Jefferies 2nd Annual Healthcare,Conference ... presentation is,scheduled for Wednesday, June 25 at 3:15pm ...
... To Actively Pursue Acquisition Opportunities -, BRIDGEWATER, N.J. ... specialty pharmaceutical company, today announced,its launch backed by Warburg ... made an initial investment in GANIC from Warburg,Pincus Private ... in April., GANIC Pharmaceuticals was founded by a ...
... - Sale of Consumer Healthcare Business, - ... Science, Gerresheimer AG, the leading manufacturer of ... science industry, is selling its consumer healthcare,business. As ... which are not part of the core business ...
Cached Biology Technology:Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 3Gerresheimer Discontinues Marginal Operations 2
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the recent success of the Wocket™ smart wallet at CES 2015 ... wallet was named as one of the "11 Hot Products at CES" ... Launched At CES So Far" by Newseveryday.com and "The top 10 gadgets ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... scientists have identified the behaviour of the mutant protein ... potential targets to treat the disease, a University of ... disease with no cure, characterized by a steady decline ... brain cells. The cause of the disease has long ...
... 2010) -- Earth,s climate is strongly influenced by the presence ... form of dust, ice and pollutants -- that find their ... There, water adsorbed on the surface of these particles can ... and snow. Researchers at Spain,s Centre d,Investigaci en ...
... chemical "nanoblasts" that punch tiny holes in the protective ... for getting therapeutic small molecules, proteins and DNA directly ... bursts of laser light trigger the tiny blasts, which ... admit therapeutic agents contained in the surrounding fluid. ...
Cached Biology News:Huntington's disease discovery provides new hope for treatment 2Artificially controlling water condensation leads to 'room-temperature ice' 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 3Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 4
... The iCycler thermal cycler with 96 x ... nucleic acid amplification (PCR) applications. It is ... (15-100 microliter samples) that is compatible with ... temperature monitoring and control by algorithm, block, ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
Biology Products: